LearnGlossaryMarketStocksSuperinvestorsSign in

OCGN

Ocugen, Inc.

Healthcare · $349M market cap

Verdict

We can't put a fair value on OCGN right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

1 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth-53.1% a year✗
Sales growth14.8% a year✓
Free cash flow growth—?
Return on invested capital-78.1%✗

Follow OCGN

Track it on your watchlist and see the full analysis. Free.

Create a free account

Insider activity

Since Sep 9, 2026: no open-market purchases and 2 sales worth $589K. Why purchases matter

Sales

Musunuri Shankar

Chief Executive Officer · 2026-09-09

Sold

$64K

Musunuri Shankar

Chief Executive Officer · 2026-09-09

Sold

$525K

About Ocugen, Inc.

Ocugen, Inc. is a biopharmaceutical company in the clinical development phase, primarily dedicated to pioneering gene therapies aimed at treating various ophthalmic conditions leading to blindness. The company's developmental pipeline features several key candidates: OCU400: An innovative gene therapy designed to reinstate both the function and structural integrity of the retina across a broad spectrum of…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works